Prof. Sébastien PAPOT
Institut de Chimie des Milieux et des Matériaux de Poitiers,
UMR-CNRS 7285, Equipe 5
Groupe « Systèmes Moléculaires Programmés »
4 rue Michel Brunet, TSA 51106
86073 POITIERS – Cedex 9, FRANCE
Tel : +33 549 453 862
Email : email@example.com
Sébastien Papot was born at the end of the second millennium and grew up in Niort (France) with his parents and two brothers. His bachelor degree in hands, he went to the University of Poitiers (France) where he studied organic chemistry. He obtained a Ph.D. in 1998 under the supervision of Prof. Jean-Pierre Gesson. The subject of his thesis was the study of glucuronide prodrugs for cancer chemotherapy. Then, he moved successively to the University of Orléans (Prof. G. Guillaumet, France) and the University College Cork (Prof. A. Maguire, Ireland) as a post-doctoral fellow working on several projects in the area of medicinal chemistry. During his stay in Cork, he became very interested in beer, especially Irish beer. In 2003, he moved back to Poitiers to start an academic career as an Assistant Professor.
A few years later, Sébastien was contacted by the President of the French Medicinal Chemistry Society for the organization of the RICT 2012 which was held in Poitiers in July 2012, only one month after the birth of his son Gaspar. In 2014, he was the laureate of the Pierre Fabre Award for Therapeutic Innovation. The same year, he accepted a full professorship at the University of Poitiers. He is currently the group leader of the “Programmed Molecular Systems” team. His research interests include the design of smart drug delivery systems for cancer chemotherapy, functional interlocked systems and prebiotic chemistry.
– Chairman of the 48th International Conference on Medicinal Chemistry (RICT Poitiers).
– Expert for the French Medicinal Chemistry Society (SCT).
– Coordinator of the research project “ProTarget” funded by the Agence Nationale de la Recherche (2013-2015).
Top Five Papers:
“A mechanically interlocked molecular system programmed for the delivery of an anticancer drug” R. Barat, T. Legigan, I. Tranoy-Opalinski, B. Renoux, E. Péraudeau, J. Clarhaut, P. Poinot, A. E. Fernandes, V Aucagne, D. A. Leigh and S. Papot, Chem Sci. 2015.
“The First Generation of ß-Galatosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy” T. Legigan, J. Clarhaut, I. Tranoy-Opalinski, A. Monvoisin, B. Renoux, M. Thomas, A. Le Pape, S. Lerondel and S. Papot Angew. Chem. Int. Ed. 2012, 51, 11606-11610. (“Very Important Paper”, Inside Cover)
“Synthesis and Antitumor Efficacy of a ß-Glucuronidase-Responsive Albumin-Binding Prodrug of Doxorubicin” T. Legigan, J. Clarhaut,B. Renoux, I. Tranoy-Opalinski, A. Monvoisin, J.-M. Berjeaud, F. Guilhot and S. Papot J. Med. Chem. 2012, 55, 4516-4520.
“A Heterodimeric Glucuronide Prodrug for Cancer Tritherapy: the Double Role of the Chemical Amplifier” M. Grinda, J. Clarhaut, I. Tranoy-Opalinski, B. Renoux, A. Monvoisin, L. Cronier and S. Papot ChemMedChem 2011, 6, 2137-2141. (Inside Cover)
“Rotaxane-Based Propeptides: Protection and Enzymatic Release of a Bioactive Pentapeptide” A. Fernandes, A. Viterisi, F. Coutrot, S. Potok, D. A. Leigh, V. Aucagne, and S. Papot Angew. Chem. Int. Ed. 2009, 48,6443-6447. (“Hot Paper”)